[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100385614":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":92,"centralContacts":96,"locations":103,"responsibleParty":118,"collaborators":10,"id":120,"slug":121,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":10,"eligibilityCriteria":126,"healthyVolunteers":122,"sex":127,"minAge":128,"maxAge":10,"enrollmentInfo":129,"targetDuration":10,"studyType":132,"phases":10,"briefSummary":133,"conditions":134,"keywords":141,"overallStatus":105,"whyStopped":10,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,23,28,32],{"label":9,"type":10,"description":11,"interventionNames":12},"older lymphoma patients",null,"This is a prospective observational cohort where 18 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory high-grade B-cell lymphoma will undergo serial comprehensive geriatric assessment, neurocognitive testing, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.",[13,14,15,16,17,18,19,20,21,22],"Behavioral: Activities of Daily Living\u002FADLs","Behavioral: Instrumental Activity of Daily Living","Behavioral: Timed Up and Go","Behavioral: Cognition","Behavioral: Geriatric Depression Scale","Behavioral: Social Support","Behavioral: Brief Test of Attention","Behavioral: Trail Making Test","Behavioral: Controlled Oral Word Association Test","Behavioral: Hopkins Verbal Learning Test-Revised",{"label":24,"type":10,"description":25,"interventionNames":26},"older patients with lymphoma and other lymphoid malignancies","This is a prospective observational cohort where 80 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory lymphoma and lymphoid malignancies will undergo comprehensive geriatric assessment, aging biomarker analysis, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.",[13,14,15,16,17,18,19,20,21,22,27],"Other: Blood draw",{"label":29,"type":10,"description":30,"interventionNames":31},"older patients with myeloma and other plasma cell disorders","This is a prospective observational cohort where 40 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory plasma cell disorders will undergo",[13,14,15,16,17,18,19,20,21,22,27],{"label":33,"type":10,"description":34,"interventionNames":35},"older patients with lymphoma","This is prospective observational cohort where 16 older (≥60yo) lymphoma patients with pre-CAR T cognitive impairment.",[13,14,15,16,17,18,19,20,21,22,27],[37,44,50,54,58,62,66,72,76,82,88],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"BEHAVIORAL","Activities of Daily Living\u002FADLs","7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14",[9,33,24,29],[43],"ADLs",{"type":38,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"Instrumental Activity of Daily Living","8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.",[9,33,24,29],[49],"iADLS",{"type":38,"name":51,"description":52,"armGroupLabels":53,"otherNames":10},"Timed Up and Go","Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (\\\u003C10 seconds, 10-20 seconds, \\>20 seconds)",[9,33,24,29],{"type":38,"name":55,"description":56,"armGroupLabels":57,"otherNames":10},"Cognition","Mini-Cognition test: CDT and 3-word recall",[9,33,24,29],{"type":38,"name":59,"description":60,"armGroupLabels":61,"otherNames":10},"Geriatric Depression Scale","Four yes\u002Fno questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of \\>\u002F=1 is usually indicative of depression.",[9,33,24,29],{"type":38,"name":63,"description":64,"armGroupLabels":65,"otherNames":10},"Social Support","Four 5-point Likert scale questions addressing 4 domains of social support: emotional\u002F informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.",[9,33,24,29],{"type":38,"name":67,"description":68,"armGroupLabels":69,"otherNames":70},"Brief Test of Attention","assess selective auditory attention.",[9,33,24,29],[71],"BTA",{"type":38,"name":73,"description":74,"armGroupLabels":75,"otherNames":10},"Trail Making Test","Assesses visual scanning, graphomotor speed, and set shifting.",[9,33,24,29],{"type":38,"name":77,"description":78,"armGroupLabels":79,"otherNames":80},"Controlled Oral Word Association Test","A timed test of verbal fluency",[9,33,24,29],[81],"COWAT",{"type":38,"name":83,"description":84,"armGroupLabels":85,"otherNames":86},"Hopkins Verbal Learning Test-Revised","The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.",[9,33,24,29],[87],"HVLT-R",{"type":6,"name":89,"description":90,"armGroupLabels":91,"otherNames":10},"Blood draw","collection of blood tests",[33,24,29],[93],{"name":94,"affiliation":5,"role":95},"Richard Lin, MD, PhD","PRINCIPAL_INVESTIGATOR",[97,101],{"name":94,"role":98,"phone":99,"phoneExt":10,"email":100},"CONTACT","646-608-2646","ABMTTrials@mskcc.org",{"name":102,"role":98,"phone":10,"phoneExt":10,"email":100},"Sergio Giralt, MD",[104],{"facility":5,"status":105,"city":106,"state":106,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":115,"contacts":116},"RECRUITING","New York","10065","United States","US",{"type":111,"coordinates":112},"Point",[113,114],-74.00597,40.71427,{"lat":114,"lon":113},[117],{"name":94,"role":98,"phone":10,"phoneExt":10,"email":100},{"type":119,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100385614","study-of-car-t-therapy-in-older-patients-100385614",false,"NCT04300998","Study of CAR-T Therapy in Older Patients","Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation","Inclusion Criteria:\n\n* are ≥60 years old (all cohorts)\n* have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts)\n* able to speak and understand English (cohort 1 and 4 only)\n* have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only)\n\nExclusion Criteria:\n\n* Any prior commercial or investigational CAR T therapy (all cohorts)\n* Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only)\n* History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\\>60 minutes), as per medical records or patient report (cohort 1 only)\n* Current ongoing substance abuse and\u002For history of substance abuse, as per medical records or patient report (cohort 1 only)\n* History of CNS disease (cohort 4 only)","ALL","60 Years",{"count":130,"type":131},154,"ESTIMATED","OBSERVATIONAL","This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.",[135,136,137,138,139,140],"Lymphoma","Refractory B-Cell Lymphoma","Lymphoma, B-Cell","DLBCL NOS","High-grade B-cell Lymphoma","Multiple Myeloma",[135,142,143,139,138,136,144,5],"CART therapy","relapsed refractory large B-cell lymphoma","19-452","2026-04-01",{"date":147,"type":148},"2026-04-07","ACTUAL",{"date":150,"type":148},"2020-03-04",{"date":152,"type":131},"2027-03-04",{"name":5,"class":6},1]